GlassScriptPhysician profile
Donna Allison Hall
NPI 1710984182
$5,579.13
in general payments reported to CMS, 2019-2025
36 companies · $1,885 in 2025
The $1,885 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $340 · 2022: $698 · 2023: $922 · 2024: $1,734 · 2025: $1,885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,441 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,441.37 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $942.67 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $909.66 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $614.11 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $549.78 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $439.16 | 2021-2025 | |
| Glaxosmithkline, LLC. | $355.38 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $352.90 | 2023-2025 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $177.68 | 2022-2025 | Rexulti |
| Exact Sciences Corporation | $143.23 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $103.45 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.49 | 2021-2022 | |
| Abbott Laboratories | $85.05 | 2021-2025 | Freestyle Libre 2, Proclaim |
| Corcept Therapeutics | $70.56 | 2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.56 | 2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $60.81 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.38 | 2025 | Caplyta |
| Sumitomo Pharma America, INC. | $55.02 | 2023-2024 | Gemtesa |
| Averitas Pharma INC. | $52.10 | 2023 | Qutenza |
| Bayer Healthcare Pharmaceuticals INC. | $48.15 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.05 | 2023-2024 | Trintellix |
| Axsome Therapeutics, INC. | $34.79 | 2025 | Auvelity |
| Boston Scientific Corporation | $34.47 | 2025 | Wavewriter Alpha Prime 16 |
| Esperion Therapeutics, INC. | $33.36 | 2024 | Nexletol |
| Depuy Synthes Sales INC. | $29.59 | 2024-2025 | Monovisc, Orthovisc |
| Dexcom, INC. | $26.62 | 2023 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $23.59 | 2025 | Aptima |
| Fidia Pharma USA INC. | $21.48 | 2025 | Hymovis |
| Lundbeck LLC | $21.08 | 2024 | Rexulti |
| Philips North America LLC | $20.53 | 2025 | Extended Holter |
| Seqirus USA INC | $18.93 | 2025 | Flucelvax, Fluad |
| Radius Health, INC. | $17.20 | 2025 | Tymlos |
| Janssen Pharmaceuticals, INC | $16.80 | 2023 | Xarelto |
| Antares Pharma, INC. | $15.85 | 2024 | Xyosted |
| Xeris Pharmaceuticals, INC. | $14.15 | 2024 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $13.79 | 2022 | |
| Smith+Nephew, INC. | $13.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.